11/20
08:32 am
eldn
Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Medium
Report
Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
11/14
06:27 am
eldn
Eledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) market cap dropped US$48m last week; individual investors who hold 57% were hit as were institutions [Yahoo! Finance]
Medium
Report
Eledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) market cap dropped US$48m last week; individual investors who hold 57% were hit as were institutions [Yahoo! Finance]
11/12
04:12 pm
eldn
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results [Yahoo! Finance]
High
Report
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results [Yahoo! Finance]
11/12
04:01 pm
eldn
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results
High
Report
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results
11/6
04:05 pm
eldn
Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference
Low
Report
Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference
10/29
07:46 am
eldn
Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Medium
Report
Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
10/29
07:45 am
eldn
Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine
Medium
Report
Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine